News Hub | News Direct

Transportation

Airlines Automotive Electric Vehicles Logistics Maritime
Article thumbnail News Release

New Horizon Aircraft (NASDAQ: HOVR) Poised For Growth With Hybrid Aircraft Technology Amid Small-Cap Strength

Benzinga

By Gerelyn Terzo, Benzinga The future has arrived, thanks to electric Vertical Take-Off and Landing (eVTOL) aircraft. eVTOLs are aircraft that launch vertically, similar to a helicopter, rather than a conventional takeoff. Hybrid-electric eVTOL designs have the potential to enable greater speed, range and cargo capacity than fully electric versions and could play an important role in the future of aviation. While eVTOL is still in its early days, with the industry currently in the testing phase, its value is predicted to surpass $30 billion by the next decade amid a CAGR of 15.3% since last year. And while Tesla (NASDAQ: TSLA) is playing a key role with electric vehicles, New Horizon Aircraft (NASDAQ: HOVR) hopes to take on a leadership position in the eVTOL aircraft market segment. Toronto-based New Horizon says it has been an early mover in eVTOL technology with its Cavorite X7 prototype aircraft, a hybrid model built for real-world use cases. Its aircraft takes off vertically, true to eVTOL form. However, once in flight, it reverts to the configuration of a conventional airplane, owing to the company’s patented HOVR wing system. The Cavorite X7 is built to reach speeds of 250 miles per hour, with a fuel capacity of more than 500 miles, making it appropriate for real-world applications like travel when the time comes. Learn more about New Horizon Aircraft’s technology here. New Horizon Puts Pedal To The Metal On eVTOL Aircraft Led by a team of operators, aviators and aerospace engineers, New Horizon has been going full throttle of late as it prepares to fully transition its large-scale prototype aircraft by the end of this year. Chief among New Horizon’s priorities is advancing the development of its hybrid-powered eVTOL aircraft. The company has been making strides from a technical standpoint while also building out its team internally. Flight test program: Among the technical highlights, New Horizon has published results on its flight test program, which it says are surpassing its expectations. The company has performed hundreds of flight tests and is nearing full transition speed, which it anticipates achieving by year-end. Full-scale aircraft development: New Horizon says it is innovating the proprietary patent technologies that are critical to its unique aircraft, including full-scale propulsion units that are essential to its HOVR wing technology. Cooling system and power tests for its full-scale propulsion units continue to unfold and it says the outcomes are positive so far. Encouraging test results extend to the company’s Cavorite X7’s patented HOVR wing design, which the company says enables safer, more durable performance even in the most forbidding conditions. Digital twin development: New Horizon harnesses a hardware-in-the-loop (HITL) digital twin technology to test its aircraft, supporting the rapid testing of large-scale prototype aircraft like the Cavorite X7. Its hybrid technology is fueled by its HOVR wing technology, allowing the aircraft to fly nearly all of its missions in a formation that closely resembles that of a conventional aircraft. Meanwhile, the company says the hybrid power system delivers greater range, speed and payloads in its class. When the Cavorite X7 reaches commercialization, New Horizon expects it to have the power to disrupt the travel industry with its speed, efficiency and cost savings over traditional aircraft. However, its potential use cases also extend to medical evacuation, critical supply delivery, disaster relief and special military missions. “Our unique, customer-first approach prioritizes building a tough eVTOL aircraft that can operate in bad weather, icing conditions and other challenging operational environments. This strategy is gaining strong traction with operators, driving substantial demand,” said Horizon Aircraft CEO Brandon Robinson. To keep pace with this ongoing innovation, New Horizon recently expanded its team with the addition of seasoned engineer Tom Brassington as Chief Technology Officer. New Horizon Says It Could Be Poised To Benefit From Possible Small-Cap Stock Demand Earlier this year, New Horizon made its debut in the publicly traded markets amid a business combination with special purpose acquisition company (SPAC) Pono Capital Three. Most recently, New Horizon returned to the equity capital markets with a $2.9 million public offering. The deal, the closing for which was announced in August, comprised 2.8 million Class A ordinary shares with various types of warrants. New Horizon’s timing is no coincidence, as the company says it could be poised to benefit from an expected ongoing rotation in the equity markets into small cap stocks. While small cap stocks have been gaining attention of late, New Horizon took matters into its own hands. It commissioned its own global poll of investment managers to uncover evidence of investor demand for small- and micro-cap names working with more sustainable technologies, where the upside potential is considered greater than larger companies because they are coming from a lower base. The aerospace company says it found that investor demand is in fact there, with more than three-quarters of survey participants demonstrating an expectation for exposure to these asset classes among institutional investors to increase in the next six to twelve months. Slightly more than one-third (34%) of them say allocations to these stocks could increase by at least 25%. Investors who are interested in participating in New Horizon’s growth story can learn more about this company’s financials here. Read more about New Horizon Aircraft: Pilotless Planes Are Coming, But Not Just Yet, Says New Horizon Aircraft CEO On The Horizon: How One Company Plans To Use Its Innovative Aircraft Design To Revolutionize Regional Air Travel From Stage To Stage: How New Horizon Aircraft's eVTOLs Could Simplify Tour Logistics For Taylor Swift Sustainably Featured photo by ELG21 on Pixabay Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 19, 2024 08:45 AM Eastern Daylight Time

Image
Article thumbnail News Release

Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian

Global Markets News

Summit Therapeutics (NASDAQ: SMMT) recently captured headlines with the release of its Phase 3 data for ivonescimab, a targeted NSCLC therapy that has generated substantial buzz. The results from its trial conducted in China showed a dramatic 49% reduction in the risk of disease progression or death compared to Merck’s Keytruda, signaling a potentially disruptive force in NSCLC treatment. However, the news wasn’t without its concerns—since the trial data originates from China, there are questions about its applicability to broader, global populations. As noted by BMO Capital Markets’ Evan Seigerman: “Results may or may not be generalizable beyond the China-focused patient population initially assessed.” Despite this, Summit’s valuation has risen by over 100%, now approximating $19 billion. With such a high valuation, the company could see limited room for further significant gains, leading many in the industry to explore other emerging opportunities in precision oncology. Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising initial results and could see similar success in the future if they were to report positive results. These emerging players are worth watching for those interested in following precision oncology drug candidates and pipelines. Among them are precision oncology innovators such as Silexion Therapeutics, Nuvectis Pharma, and Scorpion Therapeutics, which we discuss below. Silexion Therapeutics: Disrupting the KRAS-Driven Cancer Space Silexion Therapeutics (NASDAQ: SLXN) is another under-the-radar player in the precision oncology space, with a focus on KRAS-driven cancers—a notoriously difficult target in oncology. While current small-molecule KRAS inhibitors are making progress, they are often limited to specific mutations, such as KRAS G12C, which accounts for a small percentage of cancers. Silexion’s RNA interference (RNAi) approach offers a broader solution, targeting a wider spectrum of KRAS mutations, particularly in pancreatic cancer, one of the deadliest and most treatment-resistant cancers. At the heart of Silexion’s approach is its LODER™ platform, which delivers siRNA directly to the tumor site, silencing KRAS mutations at the genetic level. This localized delivery not only increases efficacy by concentrating the treatment in the tumor, but it also reduces systemic side effects. Silexion’s next-generation candidate, SIL-204, is an optimized siRNA formulation designed to target pan-KRAS G12x mutations, positioning it to treat a broader range of KRAS-driven cancers beyond pancreatic cancer, such as lung and colorectal cancers. In Phase 2 trials for locally advanced pancreatic cancer, Silexion's LODER™ platform showed a 9.3-month improvement in overall survival when combined with standard chemotherapy. Additionally, the objective response rate (ORR) increased from 20% with chemotherapy alone to 55% with the combination, and in some cases, tumors that were initially non-resectable became operable after treatment with LODER™. These results are especially encouraging given the limited options available for pancreatic cancer patients. SIL-204, is expected to enter Phase 2/3 clinical trials in 2025-2026. What makes Silexion particularly intriguing is its current market valuation. Valued at aproximatly just ~$9 million following its SPAC merger, the company’s valuation could be perceived as low when compared to some of its peers, especially given its innovative technology and promising clinical achievements. Some have wondered whether this low valuation has more to do with dynamics post-SPAC companies. If Silexion can report positive results in its later-stage trials, the company’s outlook could dramatically improve, reflecting the potential of its RNAi-based platform. Like NXP900, SIL-204 could potentially have vast applications across multiple KRAS-driven cancer types, making Silexion a company to watch closely as it advances through clinical development. Nuvectis Pharma: Targeting NSCLC and Beyond by Inhibiting SRC/YES1 Kinases Nuvectis Pharma (NASDAQ: NVCT) has been quietly making strides in the precision oncology sector, developing innovative therapies aimed at overcoming treatment resistance in hard-to-treat cancers. Its lead candidate, NXP900, targets NSCLC by inhibiting the SRC/YES1 kinases, which play critical roles in cancer cell survival and resistance to current therapies. This approach positions NXP900 as a potential game-changer in the treatment of NSCLC, particularly in patients who have developed resistance to EGFR and ALK inhibitors, such as AstraZeneca’s Tagrisso and Novartis’ Alecensa. NXP900 is still in the early stages of clinical development, currently undergoing Phase 1 trials. However, preclinical studies have already shown that it has strong anti-tumor activity in resistant NSCLC models. Even more promising is its potential application beyond NSCLC. Like Summit's ivonescimab, NXP900 focuses on resistance, but it also has broader applications due to its ability to target multiple cancer types driven by SRC/YES1 pathways. This versatility makes it a promising asset not just for NSCLC but also for other difficult-to-treat cancers like squamous cell carcinomas. In addition to NXP900, Nuvectis is advancing NXP800, another precision oncology candidate that is further along in the clinical development process. NXP800 is currently in Phase 1b trials, targeting ARID1a-mutated cancers such as ovarian and endometrial cancers. The early clinical data for NXP800 is promising, showing positive responses in patients with platinum-resistant ovarian cancer. With two strong candidates in the pipeline, Nuvectis is positioning itself as a formidable player in the precision oncology landscape. As Summit’s ivonescimab continues to gain attention, Nuvectis’ earlier-stage NXP900, with its NSCLC focus and beyond, could see similar success in the future if clinical results continue to trend positively. Scorpion Therapeutics: Pioneering Mutant-Selective Therapies Scorpion Therapeutics is redefining the frontier of precision oncology with its focus on delivering highly selective small molecules targeting validated and previously undruggable cancer mutations. Its lead candidate, STX-478, is a mutant-selective, allosteric PI3Kα inhibitor currently in Phase 1/2 trials for advanced solid tumors. Early data presented at the ESMO Congress 2024 highlighted its potential, with STX-478 demonstrating a 23% overall response rate in breast cancer and a 21% response rate across all tumor types, positioning it as a potentially best-in-class PI3Kα inhibitor. STX-478 is notable for its ability to spare wild-type PI3Kα activity in normal tissues, avoiding the toxicities seen with previous PI3Kα inhibitors, such as hyperglycemia and rash. Tumor reductions were seen in 72% of patients treated with STX-478 as a monotherapy, with circulating tumor DNA levels dropping in 86% of patients. This mutant-selective precision could help overcome the limitations of existing PI3Kα inhibitors, which have struggled with dose-limiting toxicities. In July 2024, Scorpion raised $150 million in a Series C financing round, co-led by Frazier Life Sciences and Lightspeed Venture Partners. The additional funding will support the advancement of STX-478 and other pipeline assets, positioning Scorpion for further clinical success. Scorpion’s pipeline includes a broad range of wholly-owned compounds that target both validated and novel cancer targets, positioning the company for future expansion into larger patient populations. As STX-478 progresses through clinical development, Scorpion is poised to become a significant player in the precision oncology space, making it another company worth watching closely. Optimistic Outlook for Precision Oncology The precision oncology space is experiencing a golden era of innovation, with companies like Summit Therapeutics, Nuvectis Pharma, Silexion Therapeutics, and Scorpion Therapeutics leading the charge. As the focus shifts towards targeted therapies that address resistance mechanisms, the market is increasingly favoring companies with novel approaches and broad applications. Summit’s meteoric rise has shown that there is tremendous potential for companies that can demonstrate efficacy in overcoming cancer resistance. While Summit has already captured much of the current attention, companies like Nuvectis, Silexion, and Scorpion, with their earlier-stage pipelines, offer exciting opportunities for the industry to keep a close eye on. As these companies continue to report clinical data and advance through trials, the potential for breakthroughs in treating some of the most difficult cancers grows stronger. With targeted therapies offering the possibility of overcoming resistance without the need for chemotherapy, the future of cancer treatment looks brighter than ever. For those in the oncology space, keeping a close eye on emerging players like Nuvectis, Silexion, and Scorpion could lead to transformative developments as the field of precision oncology continues to evolve. * * * This update may include speculative forward looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. the BioTech and Pharma industries are volatile and risky and readers are advised to seek out preffesional advice in the relevent feilds from licensed profesionals. This update is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. [ https://justpaste.it/ch2qt/pdf ]. Global Markets News Network is a commercial digital brand compensated to provide coverage of news and developments related to innovative companies as detailed in the full documentation and it is thus subject to conflicts of interest. Contact Details News Coverage ronald@futuremarketsresearch.com

September 19, 2024 07:45 AM Eastern Daylight Time

Article thumbnail News Release

Car Garage Expert Offers Reliable Roadside Assistance Services in Dubai

Rev Up Marketers

Car Garage Expert, a leading name in automotive repair and maintenance, is proud to announce its dependable services roadside assistance in Dubai. As a trusted and customer-centric car garage near me in Dubai, Car Garage Expert is committed to providing rapid and reliable services that ensure motorists are never left stranded on the roads. In the fast-paced environment of Dubai, drivers require quick and efficient solutions to sudden car troubles. Whether it's a flat tire, dead battery, engine breakdown, or even lockout situations, Car Garage Expert's well-equipped team is available 24/7 to address any emergency and get drivers back on the road swiftly. Our goal is to offer peace of mind to drivers across Dubai," said Muhammad Fahad Malik, CEO of Car Garage Expert. “We understand how frustrating unexpected breakdowns can be, which is why we’ve designed our roadside assistance services to be fast, reliable, and affordable. Our team is just a phone call away to ensure you’re never stuck for long.” Car Garage Expert’s state-of-the-art facility is also equipped to handle a wide range of repairs and maintenance, ensuring that drivers receive comprehensive automotive care. The garage's skilled technicians have vast experience working with all car models, making Car Garage Expert a top choice for as a trusted and customer-centric garage near me in Dubai. About Car Garage Expert: Car Garage Expert is a reputable automotive repair service provider in Dubai, offering a wide range of services including regular maintenance, engine repairs, transmission servicing, and roadside assistance. With a focus on quality, transparency, and customer satisfaction, the garage has built a solid reputation as a reliable garage near me in Dubai. Contact Details Car Garage Expert Mian Muhammad Fahad cargarageexpertdxb@gmail.com Company Website https://CarGarageExpert.com

September 17, 2024 09:21 AM Eastern Daylight Time

Image
Article thumbnail News Release

Flash Transforms Parking at Denver International Airport

Flash

Flash, the leading end-to-end parking technology platform, announced today it has completed an overhaul of public and employee parking at Denver International Airport (DEN) through a contract the City and County of Denver awarded in August 2024. In just 22 days, Flash deployed its platform across the airport’s nine public and employee parking garages and lots, bringing a state-of-the-art parking experience to DEN’s 40,000 employees and the 77.8 million passengers they serve annually. "Flash’s commitment to DEN has been tremendous and we look forward to a bright future that provides innovative solutions to improve the customer experience," said Mark Nagel, Senior Vice President of Parking and Commercial Transportation, Denver International Airport. In its first few weeks of deployment, DEN reports improved traffic flow and reduced wait times for vehicles entering and exiting the airport’s parking facilities. DEN’s deployment of Flash’s platform spans 144 lanes and features 137 kiosks, 97 license plate recognition (LPR) lanes, and 49 automatic vehicle identification (AVI) lanes. With the new AVI lanes, employees can enter and exit automatically in seconds via vehicle-mounted passes that require no interaction with their phones or kiosks. “DEN is the sixth busiest airport in the world and sees millions of parking transactions each year, requiring the highest service level,” said Flash CEO Dan Sharplin. “Our technology breadth and industry-leading scale, plus our maniacal focus on the driver experience, made us confident we could support DEN’s traffic volumes and service levels while getting passengers and employees through parking transactions quickly, and it’s hugely gratifying to see it live.” DEN also benefits from the Flash platform’s design as an enhanced cloud-based parking solution. In the event of an internet, payment processor, network or cloud disruption, the platform maintains continuous operations and critical payment processing capabilities so the airport’s parking facilities stay up and running. About Flash Flash is a pioneering technology company bringing seamless parking and EV charging experiences to drivers through a first-of-its-kind digital ecosystem. Flash’s platform connects reservable parking and charging in the apps drivers use every day with garage, surface lot, event, and valet parking locations—connected and controlled via a cloud-based operating system with unrivaled intelligence. Customer-obsessed brands partner with Flash to deliver digital, easy-to-use, reliable, and increasingly frictionless experiences to drivers eager to pay for a solution that eliminates wasted time, excess emissions, and stress. The solution has arrived.. Visit www.flashparking.com to learn more. Contact Details Ray Young +1 512-694-6097 ray@razorsharppr.com Company Website https://www.flashparking.com/

September 12, 2024 09:00 AM Central Daylight Time

Article thumbnail News Release

This EV-Based Small Cap Has Partnerships With Walmart, NASA And The U.S. Postal Service – Is It On Your Radar?

Benzinga

By Meg Flippin, Benzinga Canoo Inc. (NASDAQ: GOEV), a high-tech advanced mobility company bringing electric vehicles – namely lifestyle delivery vehicles – to commercial operators, seems to have made strides in its quest to create a state-of-the-art EV commercial fleet. The company has inked deals with some of the biggest names in the U.S., including Walmart Inc. (NYSE: WMT), the U.S. Postal Service, the Department of Defense and even NASA. So what makes these large industry players and government agencies want to partner with a relatively unknown brand? After all, Canoo doesn’t have the name recognition of Tesla Inc. (NASDAQ: TSLA). However, it does have scalable technology, which it says sets it apart. EV Is Here to Stay Over the long haul, electric fleets for commercial and government customers have a lower total cost of ownership and don’t require costly fuel. But Canoo says it takes it a step further by using one-third the parts of traditional internal combustion engines (ICEs). The maintenance schedule is almost an afterthought thanks to its advanced computer architecture, which in most cases, can remotely diagnose and repair its EVs via over-the-air (OTA) software. The company also offers a warranty that covers up to eight years, something not common in the auto industry. Canoo is going after the last-mile delivery market with its fully electric Lifestyle Delivery Vehicles (LDV). The LDVs have a last-mile delivery optimized cabin and customized cargo space. Last-mile delivery refers to the very last step of the delivery process when a parcel is moved from one location to another. Canoo reports that it utilizes true steer-by-wire technology, reducing moving parts and cabin intrusion – resulting in more usable interior space, better driver ergonomics and the addition of a panoramic window to improve road visibility. The LDV is engineered for high-frequency stop-and-go deliveries and speedy vehicle-to-door drop-off, including grocery and food/meal delivery, says Canoo. Walmart Is In All those attributes are part of what led Walmart to select Canoo as its EV fleet provider. Walmart inked a deal to purchase 4,500 all-electric delivery vehicles from Canoo, beginning with the LDV. The retailer has the option to purchase up to 10,000 units. The vehicles are to be used to deliver online orders in a sustainable way which will also contribute to Walmart’s goal to achieve zero emissions by 2040, the companies said when originally announcing the deal. Canoo is headquartered in Justin, TX, and operates manufacturing sites in Oklahoma. While that is Canoo’s biggest order to date, the company is also making inroads with the U.S. government, inking deals with NASA, the Department of Defense and the U.S. Postal Service. All have the potential to expand into something more. Take the U.S. Post Office deal for starters. The postal service agreed to buy six right-hand drive versions of the LDV 190 as part of its move to electrify and modernize the postal service’s delivery fleet. Canoo delivered the vehicles this May, and the USPS is using them on mail routes. Additionally, the USPS is investing $40 billion to upgrade and improve the organization's processing, transportation and delivery networks. If it likes what it sees from Canoo, that could mean more purchases down the road. Meanwhile, NASA had also purchased three Crew Transportation Vehicles (CTVs) to transport the astronauts to the launch pad for the Artemis lunar missions. The CTVs are engineered to carry fully suited astronauts, flight support crew and equipment to the launch pad. “We are thrilled to be a part of the Artemis missions and to deliver NASA’s first zero-emission built for mission crew transportation vehicles,” said Tony Aquila, Chairman and CEO of Canoo. “It’s a very proud day for Canoo and all of our partners who worked so hard to ensure we perform our part to transport the astronauts for the first nine miles of every launch.” Beyond LDVs Beyond electric vehicles, Canoo is busy supplying batteries to the Department of Defense, expanding a deal with the U.S. Navy. Canoo’s proprietary battery system is modular and can support various military applications and configurations. The batteries harbor 5kWh modules that utilize 2170 cylindrical cells, but can fit other form factors and cell chemistries. The company says the expansion of the partnership further validates its technology and reliability. It is also delivering the Light Tactical Vehicle (LTV) to the U.S. Army. From fully electric vehicles that can transport cargo, goods and people to batteries powered by wind and solar, Canoo is doing its part for a greener tomorrow. It may not be a household name yet, but with some big-name players as partners, it's one investors may want to keep an eye on. Keep a look out for more Canoo Inc. announcements here. Featured photo courtesy of Canoo. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 12, 2024 09:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

CollisionRight Reaches 100 Collision Repair Shops

CollisionRight

CollisionRight LLC, a leading regional multi-shop collision repair operator, today announced the acquisition of its 100th shop. The milestone was reached within four years of the company’s founding, culminating in the rapid implementation of its initial market-entry campaign and setting the stage for an equally aggressive growth strategy that aims to increase CollisionRight’s footprint threefold over a five-year span. CollisionRight has reached its 100th-location milestone through the three-shop acquisition of Tripp’s Collision in Michigan. As with each of CollisionRight’s 41 acquisitions to date, Tripp’s will continue to do business under its market-leading local brand while benefiting from the support and efficiency of a unified, large-scale organization. All of CollisionRight’s locations are corporate-owned and run under a common operating system of management, technology, back-office support, and partnerships with insurance carriers and vendors. “Acquiring our 100th store in just a few years is a testament to the hard work and dedication of our remarkable team. It underscores the value that embracing the history of established and trusted collision repair brands can bring,” said Rich Harrison, CEO of CollisionRight. “Driven by our mission to provide exceptional customer service and create the best possible place to work, our team will continue to pursue rapid growth into the coming years.” Having reached the 100-shop milestone, CollisionRight intends to both increase its presence within the 10 states it currently serves and expand its footprint into numerous additional markets. Through strategic acquisitions of local market leaders like Tripp’s—as well as organic growth via insurance-carrier relationships, supply chain optimization, and calibration services—CollisionRight expects to triple its revenue within the next five years. About CollisionRight Headquartered in Columbus, Ohio, CollisionRight provides state-of-the-art collision repair services at 100 corporate-owned locations across 10 states: Illinois, Indiana, Kentucky, Maryland, Michigan, Ohio, Pennsylvania, Tennessee, West Virginia, and Wisconsin. Their team of more than 1,500 collision repair professionals puts more than 90,000 vehicles back on the road each year with a single priority in mind: Getting you back to GO. Every location operates under an established brand that has earned the trust of its local community through decades of prioritizing complete customer satisfaction and convenience. For more information about CollisionRight, or to contact your neighborhood collision repair shop, please visit www.CollisionRight.com. Note to the editor: the company logo, a high-resolution headshot of Rich Harrison, and a copy of the map illustrating CollisionRight’s geographical presence can be found at this link. Contact Details Razor Sharp PR Ray Young +1 512-694-6097 ray@razorsharppr.com Company Website http://www.collisionright.com/

September 11, 2024 10:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

Flash Secures $85 Million to Back Special Purpose Vehicle to Propel Growth and Provide Flexible Payment Options

Flash

Flash, the industry-leading end-to-end parking technology platform, today announced that it has closed on $85 million in debt financing for a newly formed special purpose vehicle (“SPV”) to accelerate platform adoption and offer Flash clients an expanded range of flexible payment options. The debt capital, which can be increased up to $100 million, was provided by Vantage Infrastructure (“Vantage”), a leading independent specialist infrastructure credit fund. “Asset owners and operators have a myriad of budgetary and deployment preferences – the payment options we can now extend through the SPV will allow customers to join the Flash platform on terms that work best for them," said Chris Donus, President of Flash. “Innovation in payment options is as critical as platform innovation in pursuit of our vision for the parking industry’s transformation in light of the scale and momentum we're on pace to achieve." Flash’s payment options allow clients to select amongst flexible monthly payment plans that suit their budgets, regardless of scale, asset type, or configuration. This includes EV charging infrastructure and other advanced parking technologies offered by Flash. Flash anticipates extending the SPV structure and partnership with Vantage in future financings. ”We’re pleased to support Flash with a tailored financing solution that enables their team to continue to meet and exceed their clients’ need for better transport related infrastructure,” said Nick Cleary, Senior Partner at Vantage. “This is a great example of the opportunity to upgrade and transform proven traditional infrastructure that saves time and costs for drivers and help build out the EV charging network.” Evercore acted as Flash’s exclusive financial advisor, and Cadwalader, Wickersham & Taft LLP provided legal counsel to Flash. Steptoe LLP acted as counsel to Vantage. About Flash Flash is a pioneering technology company bringing seamless parking and EV charging experiences to drivers through a first-of-its-kind digital ecosystem. Flash’s platform connects reservable parking and charging in the apps drivers use every day with garage, surface lot, event, and valet parking locations — connected and controlled via a cloud-based operating system with unrivaled intelligence. Customer-obsessed brands partner with Flash to deliver digital, easy-to-use, reliable, and increasingly frictionless experiences to drivers eager to pay for a solution that eliminates wasted time, excess emissions, and stress from driving. The solution has arrived. Visit www.flashparking.com to learn more. About Vantage Infrastructure Vantage Infrastructure is an independent infrastructure specialist manager committed to delivering sustainable investment solutions with an equity and debt infrastructure investment portfolio of over US $4 billion invested in infrastructure assets across Europe, North America, and Australia on behalf of global clients. Contact Details Razor Sharp PR Ray Young +1 512-694-6097 ray@razorsharppr.com Company Website https://www.flashparking.com/

September 09, 2024 09:00 AM Central Daylight Time

Article thumbnail News Release

NAVEX Announces 2024 Excellence Awards Finalists

NAVEX Global

NAVEX, a leading provider of integrated risk and compliance management software, announces today the 2024 NAVEX Excellence Awards finalists. Now in its fourth year, the awards celebrate organizations that demonstrate exceptional commitment to corporate governance, risk mitigation, and ethical practices. Each year, the NAVEX Excellence Awards highlight how robust governance, risk and compliance (GRC) programs can strengthen corporate culture and meaningfully impact business outcomes that matter. The 2024 finalists exemplify how effective GRC initiatives can proactively manage and mitigate risks when woven into the organizational fabric. "Congratulations to this year’s nominees and finalists for their outstanding achievements," said NAVEX Chief Customer Officer, Steve Chapman. "We are proud to partner with customers who are dedicated to advancing their GRC efforts. These awards shine a spotlight on some of the most innovative and effective programs in the industry, and we applaud the compliance teams at these companies for their ongoing efforts to build highly ethical, risk-aware organizations." The winners will be honored in several categories, including Ethics & Compliance, Risk Management, and Risk and Compliance Program of the Year. Selected from a highly competitive pool of nominations, this year’s finalists include: As in previous years, the judging panel brings together a mix of NAVEX leaders and seasoned GRC professionals. This year’s esteemed panel features: Barbara Boehler, Senior Director, Program on Corporate Compliance and Ethics, Fordham Law Bill Cameron, Founder and Principal, Cameron Advisory Services Carol Williams, CEO and Enterprise Risk Management Consultant, Strategic Decision Solutions Carrie Penman, Chief Risk and Compliance Officer, NAVEX Kyle Brasseur, Former Editor in Chief, Compliance Week Kyle Martin, Vice President of GRC Solutions, NAVEX Matt Kelly, Editor and CEO, Radical Compliance LLC Stephen Chapman, Chief Customer Officer, NAVEX Vera Cherepanova, Ethics Advocate, Consultant, Author, Studio Etica Award recipients will be announced after to the 2024 NAVEX Next Virtual Conference on October 1. NAVEX is trusted by thousands of customers worldwide to help them achieve the business outcomes that matter most. As the global leader in integrated risk and compliance management software and services, we deliver solutions through the NAVEX One platform, the industry’s most comprehensive governance, risk and compliance (GRC) information system. For more information, visit NAVEX.com and our blog. Follow us on Twitter and LinkedIn. Contact Details Navex Global +1 617-388-5773 scott.levesque@navex.com Company Website https://navex.com

September 03, 2024 08:06 AM Eastern Daylight Time

Article thumbnail News Release

Nuvectis Pharma Rises in Pre-Market Following FDA Orphan Drug Designation for NXP800, Fueling Optimism Ahead of Key Clinical Data

Global Markets News

Nuvectis Pharma (NASDAQ: NVCT) has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting Orphan Drug Designation for its lead candidate, NXP800. This designation, specifically for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers, marks a critical step forward in Nuvectis’s mission to address unmet needs in oncology. Orphan Drug Designation: A Strategic Advantage The FDA’s Orphan Drug Designation is awarded to drugs that show promise in treating rare diseases affecting fewer than 200,000 people in the U.S. For Nuvectis, this designation not only validates the potential of NXP800 but also provides several strategic benefits. These include tax credits for clinical trial costs, exemption from certain FDA fees, and potentially seven years of market exclusivity upon approval. NXP800 targets ARID1a-deficient cancers, a subset of ovarian cancers that present significant treatment challenges. The Orphan Drug Designation underscores the importance of this candidate in potentially offering a new, more effective treatment option for patients with this specific genetic mutation. Background and Market Impact This latest achievement builds on Nuvectis Pharma’s earlier successes. Earlier this year, the FDA granted Fast Track Designation to NXP800 for its development in platinum-resistant, ARID1a-mutated ovarian cancer. The Fast Track status, combined with the Orphan Drug Designation, highlights the urgent need for innovative treatments in this space and positions NXP800 as a potential game-changer in oncology. Financial analysts have taken note of Nuvectis’s progress. H.C. Wainwright recently reiterated its buy rating for Nuvectis, setting a price target of $21. This optimistic outlook reflects the market’s confidence in the company’s strategic direction, particularly as it prepares to release key clinical data later this year. Anticipation for Upcoming Results The next few months are expected to be pivotal for Nuvectis Pharma. The company is poised to share updates from its ongoing Phase 1b clinical trial of NXP800, which targets patients with platinum-resistant, ARID1a-mutated ovarian cancer. This trial is being closely watched, as positive results could significantly advance the development of NXP800, bringing it closer to pivotal trials and eventual regulatory approval. Additionally, Nuvectis is also conducting a Phase 1a dose escalation study for NXP900, its second key candidate, which targets YES1/SRC-driven tumors. Updates from this study are expected to provide further insights into the safety and potential efficacy of NXP900. ### Nuvvectis' Full announcment, titled " Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers" was published on August 29th, 2024. ### This article is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. https://justpaste.it/fcm9n/pdf. Global Markets News Network is a commercial digital brand compensated to provide coverage of innovative companies and industries and it is thus subject to conflicts of interest. Contact Details Global Markets News News Coverage ronald@futuremarketsresearch.com

August 29, 2024 08:20 AM Eastern Daylight Time

12345 ... 110